Pfizer’s Ruxience (biosimilar, rituximab) Receives FDA’s Approval for Cancer and Autoimmune Diseases

 Pfizer’s Ruxience (biosimilar, rituximab) Receives FDA’s Approval for Cancer and Autoimmune Diseases

Pfizer’s Ruxience (biosimilar, rituximab) Receives FDA’s Approval for Cancer and Autoimmune Diseases

Shots:

  • The approval is based on REFLECTIONS B3281006 study results assessing Ruxience vs reference product, Rituxan (rituximab) in patients with CD20-positive, low tumor burden follicular lymphoma
  • The REFLECTIONS B3281006 study results demonstrated biosimilarity data of Ruxience to the reference product. Ruxience is the third biosimilar of Pfizer’s oncology portfolio to be approved in the US in 2019
  • Ruxience (rituximab-pvvr) is an anti-CD20 mAb which acts by targeting CD20 present on the surface of B-cells, approved for NHL, CLL, GPA and MPA in the US and is under EMA’s review in Europe

Click here to read full press release/ article | Ref: Pfizer | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post